Fulvia Terracciano

Dr. Fulvia Terracciano


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
APAndrea Picchianti-Diamanti
Andrea Picchianti-Diamanti
CPConcetta Panebianco
Concetta Panebianco
SSSimonetta Salemi
Simonetta Salemi
MSMaria Laura Sorgi
Maria Laura Sorgi
RRRoberta Di Rosa
Roberta Di Rosa
Valerio PazienzaValerio Pazienza
Valerio Pazienza
A certain number of studies were carried out to address the question of how dysbiosis could affect the onset and development of rheumatoid arthritis (RA), but little is known about the reciprocal influence between microbiota composition and immunosuppressive drugs, and how this interaction may have an impact on the clinical outcome. The aim of this study was to characterize the intestinal microbiota in a groups of RA patients treatment-naïve, under methotrexate, and/or etanercept (ETN). Correlations between the gut microbiota composition and validated immunological and clinical parameters of disease activity were also evaluated. In the current study, a 16S analysis was employed to explore the gut microbiota of 42 patients affected by RA and 10 healthy controls. Disease activity score on 28 joints (DAS-28), erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-cyclic citrullinated peptides, and dietary and smoking habits were assessed. The composition of the gut microbiota in RA patients free of therapy is characterized by several abnormalities compared to healthy controls. Gut dysbiosis in RA patients is associated with different serological and clinical parameters; in particular, the phylum of Euryarchaeota was directly correlated to DAS and emerged as an independent risk factor. Patients under treatment with ETN present a partial restoration of a beneficial microbiota. The results of our study confirm that gut dysbiosis is a hallmark of the disease, and shows, for the first time, that the anti-tumor necrosis factor alpha (TNF-α) ETN is able to modify microbial communities, at least partially restoring a beneficial microbiota.

26 April 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
CPConcetta Panebianco
Concetta Panebianco
NTNadia Trivieri
Nadia Trivieri
AVAnnacandida Villani
Annacandida Villani
FTFulvia Terracciano
Fulvia Terracciano
TLTiziana Pia Latiano
Tiziana Pia Latiano
Valerio PazienzaValerio Pazienza
Valerio Pazienza
Chemoresistance is a major problem in the therapeutic management of pancreatic cancer, concurring to poor clinical outcome. A number of mechanisms have been proposed to explain resistance to gemcitabine, a standard of care for this malignancy, among which is included aberrant miRNA expression. In the current study, we investigated the role of miR-217, which is strongly down-regulated in cancerous, compared to normal, pancreatic tissues or cells, in sensitizing human pancreatic cancer cell lines to this drug. The low expression of miR-217 in pancreatic cancer patients was confirmed in two gene expression datasets (GSE41372 and GSE60980), and the prognostic value of two target genes (ANLN and TRPS1), was estimated on clinical data from the Tumor Cancer Genome Atlas (TCGA). Transfecting miR-217 mimic in pancreatic cancer cells reduced viability, enhanced apoptosis, and affected cell cycle by promoting a S phase arrest in gemcitabine-treated cells. Moreover, in drug-exposed cells subjected to miR-217 forced expression, a down-regulation for several genes involved in cancer drug resistance was observed, many of which are cell cycle regulators, such as CCND1, CCNE1, CDK2, CDKN1A, CDKN1B, while others, such as ARNT, BRCA1, BRCA2, ELK1, EGFR, ERBB4, and RARA are involved in proliferation and cell cycle progression. Our results support the notion that miR-217 enhances pancreatic cancer sensitivity to gemcitabine, mainly impairing cell cycle progression.

28 February 2011 in Digestive and Liver Disease
Verified
Journal Article
Closed access
GMGiovanni Maconi
Giovanni Maconi
FTFulvia Terracciano
Fulvia Terracciano
ISIlario de Sio
Ilario de Sio
CRCaterina Rigazio
Caterina Rigazio
PRPaola Roselli
Paola Roselli
Sara MassironiSara Massironi
Sara Massironi

Verified
Journal Article
Open access
PDF file
FTFrancesca Tavano
Francesca Tavano
ALAnna Latiano
Anna Latiano
OPOrazio Palmieri
Orazio Palmieri
DGDomenica Gioffreda
Domenica Gioffreda
TLTiziana Latiano
Tiziana Latiano
FPFrancesco Perri
Francesco Perri
Diagnosis of biliopancreatic cancers by the available serum tumor markers, imaging, and histopathological tissue specimen examination remains a challenge. Circulating cell-free DNA derived from matched pairs of secretin-stimulated duodenal fluid (DF) and plasma from 10 patients with biliopancreatic diseases and 8 control subjects was analyzed using AmpliSeq™ HD technology for Ion Torrent Next-Generation Sequencing to evaluate the potential of liquid biopsy with DF in biliopancreatic cancers. The median cfDNA concentration was greater in DF-derived than in plasma-derived samples. A total of 13 variants were detected: 11 vs. 1 were exclusive for DF relative to the plasma source, and 1 was shared between the two body fluids. According to the four-tier systems, 10 clinical tier-I–II (76.9%), 1 tier–III (7.7%), and 2 tier–IV (15.4%) variants were identified. Notably, the 11 tier-I-III variants were exclusively found in DF-derived cfDNA from five patients with biliopancreatic cancers, and were detected in seven genes (KRAS, TP53, BRAF, CDKN2A, RNF43, GNAS, and PIK3CA); 82% of the tier-I-III variants had a low abundance, with a VAF < 6%. The mutational profiling of DF seems to be a reliable and promising tool for identifying cancer-associated alterations in malignant cancers of the biliopancreatic tract.

1 February 2021 in Journal of Ultrasound
Verified
Journal Article
Closed access
PDF file
FTFulvia Terracciano
Fulvia Terracciano
AMAntonella Marra
Antonella Marra
AIAntonio Massimo Ippolito
Antonio Massimo Ippolito
FBFabrizio Bossa
Fabrizio Bossa
KSKrizia Sitajolo
Krizia Sitajolo
AAAngelo Andriulli
Angelo Andriulli

28 December 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
FTFulvia Terracciano
Fulvia Terracciano
AMAntonella Marra
Antonella Marra
VNVeronica Nassisi
Veronica Nassisi
CLChiara Lillo
Chiara Lillo
FBFabrizio Bossa
Fabrizio Bossa
FPFrancesco Perri
Francesco Perri
Background Abdominal ultrasound (US) is a reliable method for visualizing gastric wall layers and measuring their thickness. The objective of this study is to characterize the ultrasound features of H. pylori-induced gastritis and assess its predictive potential role for this condition. Methods A cohort of 119 patients underwent gastroscopy with biopsy and abdominal US to evaluate antral wall thickness (AWT), submucosal wall thickness (SLT), mucosal wall thickness (MLT), gastric motility, and the presence of ingested material. They were divided into three groups: group A (normal mucosa without H. pylori infection), group B (gastritis H. pylori negative) and group C (gastritis H. pylori positive). Results: SLT and reduced gastric motility were significantly increased in the H. pylori gastritis group (p < 0.001). Multivariate analysis identified SLT as the only significant independent predictor of H. pylori gastritis (p < 0.001). An SLT threshold of 1.55 mm was determined as optimal for differentiating H. pylori-positive patients from -negative, yielding a sensitivity of 77% and a specificity of 72%. Conclusions These findings suggest that H. pylori gastritis is characterized by submucosal layer thickening and impaired gastric motility.